Study of an Investigational Nasal Aerosol or Placebo in Children (Ages 4 to 11) With Perennial Allergic Rhinitis (PAR)

Summary

The purpose of this study is to evaluate the efficacy and safety of Beclomethasone dipropionate (BDP) nasal aerosol in subjects with Perennial Allergic Rhinitis (PAR).

Timeline

Start

2013-01

Primary completion

2013-10

Completion

2013-10

Outcome

Met primary endpoint

registry BDP Nasal Aerosol 80 mcg/Day vs Placebo Nasal Aerosol; p = 0.002; LSM treatment difference from placebo -0.66 (95% CI -1.08 to -0.24) NCT01783548 ↗

Publications

• Berger WE, Jacobs RL, Amar NJ, Tantry SK, Li J, Small CJ. Efficacy and safety of beclomethasone dipropionate nasal aerosol in children with perennial allergic rhinitis. Ann Allergy Asthma Immunol. 2015 Aug;115(2):130-6. doi: 10.1016/j.anai.2015.05.012. Epub 2015 Jun 24.

Drugs

Indications